NCT04644770 2026-03-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT01923506 2025-11-26
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05079698 2025-11-10
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT01655836 2025-09-11
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT03477864 2025-04-29
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Thomas Jefferson University
Phase 1 Withdrawn
NCT02572284 2023-01-19
Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02206334 2022-05-25
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
NRG Oncology
Phase 1 Completed
NCT02653248 2022-02-09
SBRT for Organ Confined Prostate Cancer
Northwell Health
Phase 1 Completed
NCT02946008 2019-11-27
Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed